Calendar

««Jul 2009»»
SMTWTFS
   
1
2
3
4
567891011
12131415161718
19202122232425
262728293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate



Link to Ai profile Link to Anxiety Community Link to Wellsphere

Health Wisdom

IBS Tales Hope Award

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

Recommended links

Depression is Real's Down & Up Show
Weekly audio-casts from the Depression Is Real Coalition

Teen Drug Abuse Intervention
Help fight teen drug abuse, we provide information to help fight teen drug abuse by prevention and intervention.
www.teendrugabuse.us


we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 2,584,258
since: 14 May 2006

Nicotine receptor stimulant trebles the odds of stopping smoking

The new anti-smoking drug varenicline was first licensed for use in the UK on 5th December 2006. An early Cochrane Review' of its effectiveness shows that it can give a three-fold increase in the odds of a person quitting smoking. Varenicline is the first new anti-smoking drug in the last ten years, and only the third, after NRT and bupropion, to be licensed in the USA for smoking cessation.

This conclusion was drawn by a group of Cochrane researchers after they studied data from six trials that compared the effects of giving people either varenicline or a placebo. Together the trials involved 2451 people on varenicline and 2473 people on placebos.

Pooling the data showed that people taking varenicline increased their odds of quitting approximately three-fold for 12 months or longer compared with those on placebo drugs.

Data from some of the trials also showed that people given varenicline increased their odds of quitting more than 1.5-fold compared with those given bupropion, an antidepressant drug that roughly doubles a person's chance of stopping smoking.

"What we need now are some trials that make direct comparisons between varenicline and nicotine replacement therapy" says Lead Review Author Kate Cahill, who works in the Department of Primary Health Care at Oxford University.


Cahill K, Stead LF, Lancaster T.
Nicotine receptor partial agonists for smoking cessation.
Cochrane Database Syst Rev. 2007 (1) CD006103   [Abstract+Full text]